Early FDG PET in Melanoma

Inclusion Criteria:

- Adult patients, at least 18 years of age

- History of histologically confirmed melanoma as assessed per medical record review.

- Eligible for the trial UPCC #01615, "A Phase Ib Tissue Collection Study of
Pembrolizumab (MK-3475) in Subjects with Resectable Advanced Melanoma."

- Participants must be informed of the investigational nature of this study and provide
written informed consent in accordance with institutional and federal guidelines prior
to study-specific procedures.

Exclusion Criteria:

- Females who are pregnant or breast-feeding at the time of screening will not be
eligible for this study. Female participants of child-bearing potential will have a
urine or serum pregnancy test at the time of the screening visit.

- Inability to tolerate imaging procedures in the opinion of the investigator or
treating physician.

- Serious or unstable medical or psychological conditions that, in the opinion of the
investigator would compromise the subject's safety or successful participation in the
study.

- Ineligible for the trial UPCC #01615, "A Phase Ib Tissue Collection Study of
Pembrolizumab (MK-3475) in Subjects with Resectable Advanced Melanoma."

- Only individuals (aged 18 or over) who can understand and give informed consent will
be eligible to participate in this study. Individuals who are considered to be
mentally disabled will not be recruited for this study. All subjects must be able to
give informed consent. We will not be using specific methods to assess decisional
capacity. Economically disadvantaged persons will not be vulnerable to undue
influence, as this study offers no compensation. All individuals will be told that
their choice regarding study participation will in no way change their access to
clinical care. This should negate any undue influence or coercion. Children, fetuses,
neonates, or prisoners are not included in this research study.